COPENHAGEN, Denmark, April 22, 2024 “ Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding...
COPENHAGEN, Denmark, April 16, 2024 “ Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors™...
Morris & Dickson is the First U.S. Distributor for Bavarian Nordic’s JYNNEOS®, the Only FDA-approved Mpox Vaccine
After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market.
COPENHAGEN, Denmark, March 21, 2024 “ Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on...
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
Report of transactions of shares and related securities of Bavarian Nordic
Bavarian Nordic Publishes Annual Report 2023
Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. ...
Bavarian Nordic halts cancer vaccine program